Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

ClinicalTrials.gov ID: NCT03399552

Public ClinicalTrials.gov record NCT03399552. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 12, 2026, 7:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Efficacy and Safety Study of Avelumab Plus SBRT in Malignant Mesothelioma (MPM)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out whether the combination of avelumab and SBRT is safe and what effect avelumab has on mesothelioma when given in combination with SBRT. In addition, a goal of this protocol is to study the effect of radiation therapy on the immune system. It is thought that radiation treatment may create a form of 'vaccine' against cancer inside the body and immunotherapy may improve this effect. The combination of radiation treatment and immunotherapy may be more effective against cancer than either radiation or immunotherapy alone.

Study identification

NCT ID
NCT03399552
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Enrollment
15 participants

Conditions and interventions

Interventions

Drug · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 19, 2017
Primary completion
Jan 19, 2023
Completion
Jan 19, 2023
Last update posted
Oct 22, 2023

2017 – 2023

United States locations

U.S. sites
7
U.S. states
2
U.S. cities
7
Facility City State ZIP Site status
Memorial Sloan Kettering at Basking Ridge Basking Ridge New Jersey 07920
Memorial Sloan Kettering Monmouth Middletown New Jersey 07748
Memorial Sloan Kettering Commack Commack New York 11725
Memorial Sloan Kettering Westchester Harrison New York 10604
Memorial Sloan Kettering Cancer Center New York New York 10065
Memorial Sloan Kettering Rockville Centre Rockville Centre New York 11570
Memorial Sloan Kettering Nassau Uniondale New York 11553

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03399552, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 22, 2023 · Synced Sep 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03399552 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →